Bitolterol

Bitolterol

Systematic (IUPAC) name
(RS)-[4-(1-Hydroxy-2-tert-butylamino-ethyl)-2-(4-methylbenzoyl)oxy-phenyl] 4-methylbenzoate
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601236
Identifiers
CAS Number	30392-41-7
ATC code	R03AC17 (WHO)
PubChem	CID: 35330
DrugBank	DB00901
ChemSpider	32525
UNII	9KY0QXD6LI Y
ChEMBL	CHEMBL1201295 Y
Chemical data
Formula	C28H31NO5
Molecular mass	461.549 g/mol
SMILES O=C(Oc2cc(ccc2OC(=O)c1ccc(cc1)C)C(O)CNC(C)(C)C)c3ccc(cc3)C

Bitolterol mesylate (Tornalate) is a short-acting β₂ adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. In these disorders there is a narrowing of the airways (bronchi and their ramifications) that carry air to the lungs. Muscle spasm and inflammation within the bronchi get worse this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.

Colterol

Bitolterol is a prodrug of colterol. It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours. The drug, alone or in co-administration with theophylline, doesn't show cardiotoxic effect.

The U.S. Food and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market by Élan Pharmaceuticals in 2001.